Edmonds Duncan Registered Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Edmonds Duncan Registered Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,969	Closed	-$237K	–	136
2022 Q2	$237K	Hold	2,969	–	–	0.08%	101
2022 Q1	$312K	Buy	2,969 +190	+7%	+$18.5K	0.09%	103
2021 Q4	$245K	Buy	2,779 +24	+0.9%	+$2.62K	0.06%	118
2021 Q3	$302K	Buy	2,755 +115	+4%	+$11.9K	0.09%	106
2021 Q2	$247K	Buy	2,640 +29	+1%	+$2.67K	0.08%	116
2021 Q1	$240K	Buy	2,611 +69	+3%	+$5.82K	0.08%	113
2020 Q4	$221K	Buy	+2,542	New	+$189K	0.07%	118

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Edmonds Duncan Registered Investment Advisors's HZNP Position: Q3 2022 in Review

Edmonds Duncan Registered Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 2,969 shares — an estimated $237K sold.

Edmonds Duncan Registered Investment Advisors first reported a position in HZNP in Q4 2020 and held it in 7 quarters. The position peaked at $312K in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Edmonds Duncan Registered Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Edmonds Duncan Registered Investment Advisors sold 2,969 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $237K.
Edmonds Duncan Registered Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 7 quarters.
Edmonds Duncan Registered Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $312K in Q1 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Edmonds Duncan Registered Investment Advisors's 13F filing for Q3 2022, filed 14 Oct 2022.